Lipoprotein-associated phospholipase A2 and risks of coronary heart disease and ischemic stroke in the general population: A systematic review and meta-analysis
- 1 August 2017
- journal article
- review article
- Published by Elsevier in Clinica Chimica Acta
- Vol. 471, 38-45
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2 (Lp-PLA2 ): a reviewLipids in Health and Disease, 2011
- Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studiesThe Lancet, 2010
- Lipoprotein-Associated Phospholipase A2 Activity and Incident Coronary Heart Disease Among Men and Women With Type 2 DiabetesDiabetes, 2010
- Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck studyEuropean Heart Journal, 2008
- Lipoprotein-Associated Phospholipase A2 Is an Independent Predictor of Incident Coronary Heart Disease in an Apparently Healthy Older PopulationJACC, 2008
- Lp-PLA2 activity and mass are associated with increased incidence of ischemic strokeAtherosclerosis, 2008
- Lipoprotein-Associated Phospholipase A2 Activity Is Associated With Risk of Coronary Heart Disease and Ischemic StrokeCirculation, 2005
- CDC/AHA Workshop on Markers of Inflammation and Cardiovascular DiseaseCirculation, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Anti-inflammatory properties of a platelet-activating factor acetylhydrolaseNature, 1995